New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
16:02 EDTSGNTSagent Pharmaceuticals launches Flumazenil Injection
Sagent Pharmaceuticals announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6M. As with all products in Sagent's portfolio, Flumazenil features the company's PreventIV Measures(SM) packaging and labeling, designed to help reduce medication errors.
News For SGNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
12:57 EDTSGNTOn The Fly: Midday Wrap
Subscribe for More Information
07:32 EDTSGNTSagent FY15 guidance could be 'well below' consensus, says Jefferies
Jefferies says it sees several reasons why Sagent Pharmaceuticals' upcoming FY15 guidance could fall "well below" consensus estimates. The firm believes the launch of g-Venofer and g-Nembutal could be delayed until FY16, and it thinks Sagent's base business could see enhanced competition in FY15. Jefferies lowered its price target for shares to $27 from $33 and keeps a Hold rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use